Journal
PLATELETS
Volume 27, Issue 6, Pages 497-504Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/09537104.2016.1161739
Keywords
-
Categories
Funding
- Australian National Health and Medical Research Council [1079250, 1016647, 9000220]
- Victorian State Government Operational Infrastructure Support Grant
- National Health and Medical Research Council of Australia [1079250] Funding Source: NHMRC
Ask authors/readers for more resources
The lifespan of platelets in circulation is brief, close to 10 days in humans and 5 days in mice. Bone marrow residing megakaryocytes produce around 100 billion platelets per day. In a healthy individual, the majority of platelets are not consumed by hemostatic processes, but rather their lifespan is controlled by programmed cell death, a canonical intrinsic apoptosis program. In the last decade, insights from genetically manipulated mouse models and pharmacological developments have helped to define the components of the intrinsic, or mitochondrial, apoptosis pathway that controls platelet lifespan. This review focuses on the molecular regulation of apoptosis in platelet survival, reviews thrombocytopenic conditions linked to enhanced platelet death, examines implications of chemotherapy-induced thrombocytopenia through apoptosis-inducing drugs in cancer therapy as well as discusses ex vivo aging of platelets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available